

ASX Announcement

31 January 2025

ReNerve Ltd – Investor Webinar Update

Thursday, 6 February 2025 at 11:00am (AEDT)

ReNerve Limited (ASX:RNV) ("ReNerve" or "the Company") is pleased to invite shareholders and prospective investors to an investor webinar where CEO, Dr Julian Chick.

Event Details: ReNerve Limited (ASX:RNV) Investor Webinar

Date/Time: Thursday 6 February 2025, commencing at 11:00am AEDT (8:00am AWST)

Presenter: Dr Julian Chick, CEO of ReNerve Ltd

Registration: <https://bit.ly/42ABDQy>

During the webinar, Dr Chick will provide a Company update for the Quarter ended 31 December 2024, as well as an overview for the year 2025 ahead.

This will be followed by a brief live Q&A session, where Dr Chick will be answering questions that attendees are able to submit ahead of time, or using the live Q&A feature on Zoom.

Attendees are invited to submit questions prior to the webinar to info@janemorganmanagement.com.au

This announcement has been approved for release by the Company's Board of Directors.

For further information and enquiries, please contact:

Dr Julian Chick
CEO
ReNerve Ltd
+61 (0) 417 137 291
info@renerve.com.au

Jane Morgan
Investor & Media Relations
Jane Morgan Management
+61 (0) 405 555 618
jm@janemorganmanagement.com.au



+61 (03) 9482 3940



157 Heidelberg Rd,
Northcote, VIC 3070



www.renerve.com.au

About ReNerve™ Limited

ReNerve Limited (ASX:RNV) is an Australian-based biotechnology company specialising in advanced nerve repair and regeneration solutions. The Company is focused on commercialising cutting-edge medical devices and tissue-engineering products that seek to address significant unmet needs in peripheral nerve damage patients – a critical gap in healthcare. ReNerve aims to improve patient outcomes through scientifically backed products that have been developed to enhance the human body's natural healing process, while commercialising cutting-edge, scalable products for the healthcare market. ReNerve wishes to acknowledge AusIndustry's Accelerating Commercialisation program for its support through many of the activities required to commercialise the NervAlign® Nerve Cuff™.